ARVN Q2 2023 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena

ARVNArvinas, Inc.

$907M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$55M+61.2% YoY

Gross Profit

$53M97.1% margin

Operating Income

-$75M-136.9% margin

Net Income

-$67M-122.2% margin

EPS (Diluted)

$-1.25

QoQ Revenue Growth

+67.7%

Cash Flow

Operating Cash Flow

-$89M

Free Cash Flow

-$89M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$620M

Stockholders' Equity

$464M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$55M	$34M	+61.2%
Gross Profit	$53M	$32M	+65.8%
Operating Income	-$75M	-$66M	-13.4%
Net Income	-$67M	-$70M	+4.9%